2-deoxy-2-(F-18)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology

被引：20
作者：
Freebody, John [1 ,2 ]
Wegner, Eva A. [1 ,2 ]
Rossleigh, Monica A. [1 ,2 ]
机构：
[1] Prince Wales & Sydney Childrens Hosp, Dept Nucl Med, Barker St, Randwick, NSW 2031, Australia
[2] Prince Wales & Sydney Childrens Hosp, PET, Randwick, NSW 2031, Australia
来源：
WORLD JOURNAL OF RADIOLOGY | 2014年 / 6卷 / 10期
关键词：
Positron emission tomography; Computed tomography; Fluorodeoxyglucose F18; Paediatrics; Oncology; Technical issues; Dosimetry;
D O I：
10.4329/wjr.v6.i10.741
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Positron emission tomography (PET) is a minimally invasive technique which has been well validated for the diagnosis, staging, monitoring of response to therapy, and disease surveillance of adult oncology patients. Traditionally the value of PET and PET/computed tomography (CT) hybrid imaging has been less clearly defined for paediatric oncology. However recent evidence has emerged regarding the diagnostic utility of these modalities, and they are becoming increasingly important tools in the evaluation and monitoring of children with known or suspected malignant disease. Important indications for 2-deoxy-2-(F-18)fluoro-D-glucose (FDG) PET in paediatric oncology include lymphoma, brain tumours, sarcoma, neuroblastoma, Langerhans cell histiocytosis, urogenital tumours and neurofibromatosis type.. This article aims to review current evidence for the use of FDG PET and PET/CT in these indications. Attention will also be given to technical and logistical issues, the description of common imaging pitfalls, and dosimetric concerns as they relate to paediatric oncology. (c) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码：741 / 755
页数：15
相关论文
共 145 条
[21]   Pediatric genitourinary tumors [J].
Buckley, Kevin S. .
CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) :291-296
[22]   Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients [J].
Cheng, Gang ;
Chen, Wengen ;
Chamroonrat, Wichana ;
Torigian, Drew A. ;
Zhuang, Hongming ;
Alavi, Abass .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (08) :1469-1476
[23]   Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET [J].
Chung, JK ;
Kim, YK ;
Kim, SK ;
Lee, YJ ;
Paek, S ;
Yeo, JS ;
Jeong, JM ;
Lee, DS ;
Jung, HW ;
Lee, MC .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (02) :176-182
[24]  
Claudiani F, 1995, Q J Nucl Med, V39, P21
[25]   Dual-Time-Point FDG PET/CT for the Evaluation of Pediatric Tumors [J].
Costantini, Danny L. ;
Vali, Reza ;
Chan, Jeffery ;
McQuattie, Susan ;
Charron, Martin .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2013, 200 (02) :408-413
[26]   Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma [J].
Crocchiolo, R. ;
Fallanca, F. ;
Giovacchini, G. ;
Ferreri, A. J. M. ;
Assanelli, A. ;
Verona, C. ;
Pescarollo, A. ;
Bregni, M. ;
Ponzoni, M. ;
Gianolli, L. ;
Fazio, F. ;
Ciceri, F. .
ANNALS OF HEMATOLOGY, 2009, 88 (12) :1229-1236
[27]   FDG-PET as a prognostic factor in high-grade astrocytoma [J].
De Witte, O ;
Lefranc, F ;
Levivier, M ;
Salmon, I ;
Brotchi, J ;
Goldman, S .
JOURNAL OF NEURO-ONCOLOGY, 2000, 49 (02) :157-163
[28]  
Del Mar Gonzalez-Barroso M, 2000, Obes Rev, V1, P61, DOI 10.1046/j.1467-789x.2000.00009.x
[29]   18F-FDG PET in children with lymphomas [J].
Depas, G ;
De Barsy, C ;
Jerusalem, G ;
Hoyoux, C ;
Dresse, MF ;
Fassotte, MF ;
Paquet, N ;
Foidart, J ;
Rigo, P ;
Hustinx, R .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (01) :31-38
[30]   Detection of bone lesions in Langerhans cell histiocytosis: Complementary roles of scintigraphy and conventional radiography [J].
Dogan, AS ;
Conway, JJ ;
Miller, JH ;
Grier, D ;
Bhattathiry, MM ;
Mitchell, CS .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1996, 18 (01) :51-58
12345678910